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Abstract: BACKGROUND Cerebral embolic protection devices (CEPDs) have emerged as a mechanical
barrier to prevent debris from reaching the cerebral vasculature, potentially reducing stroke incidence.
Bovine aortic arch (BAA) is the most common arch variant and represents challenge anatomy for CEPD
insertion during transcatheter aortic valve replacement (TAVR). METHODS Cohort study reporting the
SentinelT M Cerebral Protection System insertion’s feasibility and safety in 165 adult patients submitted
to a transfemoral TAVR procedure from April 2019 to April 2020. Patients were divided into 2 groups:
(1) BAA; (2) non-BAA. RESULTS Median age, EuroScore II, and STS score were 79 years (74-84), 2.9%
(1.7-6.2), and 2.2% (1.6-3.2), respectively. BAA was present in 12% of cases. Successful two-filter insertion
was 86.6% (89% non-BAA vs. 65% BAA; p = 0.002), and debris was captured in 95% (94% non-BAA vs.
95% BAA; p = 0.594). No procedural or vascular complications associated with Sentinel insertion and
no intraprocedural strokes were reported. There were two postprocedural non-disabling strokes, both in
non-BAA. CONCLUSION This study demonstrated Sentinel insertion feasibility and safety in BAA. No
procedural and access complications related to Sentinel deployment were reported. Being aware of the
bovine arch prevalence and having the techniques to navigate through it allows operators to successfully
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Abstract: Background: Cerebral embolic protection devices (CEPDs) have emerged as a mechanical
barrier to prevent debris from reaching the cerebral vasculature, potentially reducing stroke incidence.
Bovine aortic arch (BAA) is the most common arch variant and represents challenge anatomy for CEPD
insertion during transcatheter aortic valve replacement (TAVR). Methods: Cohort study reporting
the SentinelTM Cerebral Protection System insertion’s feasibility and safety in 165 adult patients
submitted to a transfemoral TAVR procedure from April 2019 to April 2020. Patients were divided
into 2 groups: (1) BAA; (2) non-BAA. Results: Median age, EuroScore II, and STS score were 79 years
(74–84), 2.9% (1.7–6.2), and 2.2% (1.6–3.2), respectively. BAA was present in 12% of cases. Successful
two-filter insertion was 86.6% (89% non-BAA vs. 65% BAA; p = 0.002), and debris was captured in
95% (94% non-BAA vs. 95% BAA; p = 0.594). No procedural or vascular complications associated
with Sentinel insertion and no intraprocedural strokes were reported. There were two postprocedural
non-disabling strokes, both in non-BAA. Conclusion: This study demonstrated Sentinel insertion
feasibility and safety in BAA. No procedural and access complications related to Sentinel deployment
were reported. Being aware of the bovine arch prevalence and having the techniques to navigate
through it allows operators to successfully use CEPDs in this anatomy.
Keywords: cerebral protection device; transcatheter aortic valve replacement; stroke; cerebrovascular
events; bovine aortic arch
1. Introduction
Although newer-generation transcatheter heart valve devices and increased operator experience
have reduced the incidence of cerebrovascular events during transcatheter aortic valve replacement
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(TAVR) [1,2], stroke remains one of the most feared procedural complications. This concern is especially
relevant since TAVR is moving to low-risk and younger patients, a population in which a cerebrovascular
event has even more impact on survival and quality of life [3–6].
Cerebral embolic protection devices (CEPDs) have been developed to work as a mechanical barrier
to prevent embolic debris from reaching the cerebral vasculature, potentially reducing neurological
events during TAVR procedures. The dual-filter-based SentinelTM Cerebral Protection System (Sentinel)
(Boston Scientific, Marlborough, MA, USA) received CE Mark approval in 2013 and Food and Drug
Administration (FDA) approval in 2017, and it is now the most widely used CEPD system [7,8].
Although no single study had demonstrated Sentinel benefits in terms of hard outcomes,
two recently published propensity scoring match analyses have suggested that Sentinel use was
associated with reduced post-procedural stroke and mortality rates. In the Society of Thoracic
Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry,
after propensity-weighted analysis, significant reduction in in-hospital stroke [relative risk (RR) 0.82;
95% confidence interval (CI) 0.69-0.97], in-hospital death or stroke (RR 0.84; 95% CI 0.73-0.98), 30-day
stroke (RR 0.85; 95% CI 0.73-0.99), and 30-day mortality rate (RR 0.78; 95% CI 0.64-0.95) was observed in
patients submitted to a protected TAVR [9]. Corroborating these findings, another propensity-weighted
analysis from the National Inpatient Sample showed that Sentinel use was associated with lower risk
of in-hospital ischemic stroke [odds ratio (OR) 0.24; 95% CI 0.09-0.62] and in-hospital death (0 vs. 1%;
p = 0.036) [10].
Bovine aortic arch is the most common aortic arch variant and occurs when the brachiocephalic
artery (or innominate artery) shares a common origin with the left common carotid artery. The bovine
aortic arch prevalence is around 15% (range from 8% to 25%) [11], and its presence carries important
implications for preprocedural planning and open or endovascular interventions involving the aortic
arch. Indeed, the bovine arch has been associated with consistent geometric hostile features for
endovascular procedures, namely angulation, tortuosity, and elongation [12]. Bovine arch is also a
recognized anatomic risk factor for carotid stenting, increasing the procedural difficulty level [13],
and thoracic aortic disease development [14]. In this respect, in younger patients with this anatomical
configuration, TAVR may represent a valid option considering that they could, in time, require an open
aortic valve repair.
Regarding CEPD insertion in bovine aortic arches, though there is no formal contraindication
to apply the Sentinel system in this scenario, the angulation and tortuosity features related to this
anatomical variant are frequent reasons to preclude Sentinel use in real-life procedures. Therefore,
many patients who could benefit from cerebral protection are deprived of this strategy.
Herein, we report the feasibility and safety of Sentinel insertion in bovine aortic arch anatomy and
bovine arch prevalence in patients undergoing a TAVR procedure. This is the first study evaluating a
cohort of patients with bovine aortic arch anatomy submitted to TAVR under cerebral protection.
2. Material and Methods
Single-center cohort study. Patients who underwent a transfemoral-protected TAVR from April
2019 to April 2020 were analyzed and divided into two groups according to the aortic arch anatomy:
Group 1: Non-bovine aortic arch anatomy; Group 2: Bovine aortic arch anatomy.
All procedures involving human participants followed the institutional research committee
ethical standards in accordance with the 1964 Helsinki declaration and its later amendments. TAVR
indication decisions were driven by the institutional heart team, and patients provided written
informed consent before the procedure. Patients undergoing TAVR procedures in our institution are
included in the nationwide Swiss TAVI Registry (NCT01368250; 2016-00587), a prospective multi-center
and observational national registry collecting clinical characteristics of patients undergoing TAVR in
Switzerland, which had been previously approved by local ethics committees [15,16].
Clinical, echocardiographic, and tomographic data were collected at baseline, discharge,
and 30 days after the procedure. Clinical events were adjudicated according to the updated
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Valve Academic Research Consortium (VARC-2) criteria [17]. Combined procedures were defined
as simultaneous elective interventions, such as coronary artery angiogram, percutaneous coronary
artery intervention, left atrial appendage occlusion, intravascular lithotripsy, bioprosthetic or native
aortic scallop intentional laceration to prevent coronary artery obstruction (BASILICA), or pacemaker
generator change. Significant tortuosity was defined, based on subjective operator judgment, as a
brachiocephalic or left common carotid artery S- or C-shaped elongation or undulation, evaluated in
the preoperative computed tomography (CT) scan.
The cerebral embolic protection device used was the dual-filter-based SentinelTM Cerebral Protection
System (Sentinel) (Boston Scientific, Marlborough, MA, USA), which consists of a 6-Fr-compatible steerable
catheter (100 cm long) carrying two cone-shaped, biocompatible polyurethane filters equipped with
140 µm pores to capture and retrieve debris during TAVR procedures. The sheath is inserted through the
right radial artery, and the filters are targeted to the brachiocephalic artery (proximal target vessel) and
the left common carotid artery (distal target vessel). Using an articulating sheath, the device’s curve
can be adjusted to accommodate anatomic variations of the aortic arch (Figure 1, Movie 1). In patients
in whom the insertion of both filters was not possible, only the proximal filter was deployed. At the
end of the procedure, both filters were checked for the presence of captured material. Successful





Figure 1. Sentinel insertion in a bovine aortic arch anatomy.
3. Statistical Analysis
Quantitative data were expressed as mean ± standard deviation (SD) or median and interquartile
range (IQR). Qualitative variables were expressed as frequency and percentage. Analyses were
performed using the statistical package SPSS 19.0 software (Chicago, IL, USA). Categorical variables
were analyzed using the chi-square test, continuous variables were analyzed using the Student’s T-test
or the Mann–Whitney U test. A two-sided p-value lower than 0.05 was considered significant for
all tests.
4. Results
From April 2019 to April 2020, 231 patients were submitted to a transfemoral TAVR procedure,
165 (71.5%) of them under cerebral embolic protection. The most common reasons to preclude Sentinel
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use were significant aortic arch branch tortuosity (22.3%, n = 15); emergency procedure or procedure
performed under hemodynamic instability (10.4%, n = 7); no right radial artery suitable for Sentinel
insertion (9%, n = 6) or no Sentinel progression (3%, n = 2); aberrant right subclavian artery (3%, n = 2);
and previous left carotid endarterectomy (3%, n = 2).
Overall, bovine aortic arch (Figure 2) was identified in 37 patients (16%, n = 37/231) and in 20
(12.12%; n = 20/165) of those submitted to a protected TAVR procedure. Type I (common origin of the
brachiocephalic and left common carotid artery) bovine arch anatomy was presented in 97.3% (n = 36)
of the cases, and type II (left common carotid artery originating directly from the brachiocephalic artery,
rather than as a common trunk) in 2.7% (n = 1). Comparison between patients who received a Sentinel
device with those who did not are presented in the Supplementary Material (Table S1). There was no
difference in procedural time (55 min (46–67) vs. 51.5 min (41.7–62.7); p = 0.492) or injected contrast




Figure 2. Two examples of bovine aortic arch anatomy suitable for Sentinel insertion.
Among the 165 patients who underwent a transfemoral TAVR under cerebral protection, baseline
clinical and aortic valve characteristics were similar between the bovine and non-bovine anatomy
groups and are presented in Table 1. Significant aortic arch branch tortuosity was present in 27 patients
(16.3%; 17.2% in non-bovine vs. 2% in bovine; p = 0.412). Successful insertion of two Sentinel filters
was achieved in 143 (86.6%; 89.7% in non-bovine vs. 65% in bovine; p = 0.002). Debris was captured in
the filters of 158 patients (95.7%; 94.5% in non-bovine vs. 95% in bovine; p = 0.594).
Procedure characteristics and outcomes are presented in Tables 2 and 3, respectively. There were
no procedural or vascular complications associated with Sentinel insertion, nor intraprocedural strokes.
Two non-disabling ischemic strokes (1.21%) were reported in the non-bovine group: the first case
showed-up as aphasia on the first postoperative day, which completely regressed one day after;
the second case presented hemiplegia on the third postoperative day, which also totally regressed at
the hospital discharge. No new cerebrovascular events were reported between hospital discharge and
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30-day outpatient evaluation. Total procedure time (55 min vs. 55 min; p= 0.654) and volume of contrast
used (87mL vs. 89mL; p = 0.727) were similar in bovine and non-bovine aortic arches, respectively.
Table 1. Baseline clinical and aortic valve characteristics in patients undergoing transcatheter aortic







Age, years median (IQR) 79 (74–83) 80 (77–84) 0.318
Male gender 86 (59.3) 14 (70) 0.359
EuroScore II, % median (IQR) 2.8 (1.6–6.2) 3.2 (2.2–6.3) 0.328
STS score, % median (IQR) 2.1 (1.6–3.2) 2.8 (1.6–3.7) 0.732
Weight, Kg mean ± SD 77.2 ± 14 75.9 ± 16 0.717
Height, cm mean ± SD 166.4 ± 8 170 ± 10 0.051
Severe aortic valve stenosis 142 (97.9) 20 (100) 0.516
Aortic valve regurgitation ≥moderate 11 (6.6) 1 (5) 0.561
NYHA functional class III/IV 77 (53) 11 (55) 0.982
Arterial hypertension 103 (71) 13 (65) 0.580
Diabetes mellitus 41 (28.3) 2 (10) 0.081
Dyslipidemia 84 (57.9) 12 (60) 0.182
Coronary artery disease 64 (44.1) 12 (60) 0.191
Previous myocardial infarction 17 (12.4) 4 (20) 0.349
Previous stroke 11 (7.6) 3 (15) 0.265
Atrial fibrillation 50 (34.5) 11 (55) 0.075
Chronic obstructive pulmonary disease 17 (11.7) 3 (15) 0.674
Chronic kidney disease 44 (30.3) 6 (30) 0.975
Anemia 16 (11) 0 0.118
Peripheral artery disease 12 (8.3) 1 (5) 0.610
Active smoker 46 (31.7) 8 (40) 0.460
Previous PCI 37 (25.5) 9 (45) 0.069
Previous CABG 8 (5.5) 3 (15) 0.111
Previous aortic valve surgery 9 (6.2) 1 (5) 0.832
Previous permanent pacemaker 11 (7.6) 2 (10) 0.707
Bicuspid aortic valve 14 (9.7) 1 (5) 0.497
Aortic valve area, cm2 median (IQR) 0.75 (0.6–0.9) 0.85 (0.7–0.97) 0.099
Aortic valve mean gradient, mmHg median (IQR) 42 (35–51) 45 (37–52) 0.703
LVEF, % median (IQR) 58 (45–65) 55 (47–60) 0.301
Values expressed as numbers (%) unless otherwise indicated. IQR = interquartile range; SD = standard deviation;
CABG= coronary artery bypass graft; LVEF= left ventricular ejection fraction; NYHA=New York Heart Association;
PCI = percutaneous coronary intervention; STS = The Society of Thoracic Surgeons.







Sedation 136 (94.4) 19 (95) 0.959
Combined procedure 9 (6.2) 0 0.252
Two Sentinel filters inserted 130 (89.7) 13 (65) 0.002



















Procedure time, min median (IQR) 55 (45–67) 55 (48–61) 0.654
Contrast injection, mL median (IQR) 87 (68–130) 89 (72–145) 0.727
Values expressed as numbers (%) unless otherwise indicated. IQR = interquartile range.
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All-cause mortality 1 (0.7) 0 0.710
Permanent pacemaker implantation 20 (13.8) 5 (25) 0.190
Non-disabling stroke 2 (1.3) 0 0.516
New onset of atrial fibrillation 6 (4.1) 0 0.354
Delirium 3 (2.1) 0 0.516
Aortic valve mean gradient, mmHg median (IQR) 8.8 (5–11) 7.7 (5–9) 0.309
Aortic valve regurgitation ≤mild 135 (93.1) 18 (90) 0.909
LVEF, % median (IQR) 57 (49–63) 54 (49–57) 0.214
Hospital length of stay, days median (IQR) 5 (4–7) 6 (4–7) 0.554
Values expressed as numbers (%) unless otherwise indicated. IQR = interquartile range; LVEF = left ventricular
ejection fraction.
5. Discussion
Cerebrovascular events are one of the most devastating TAVR complications, not only in terms of
mortality but also regarding the potential sequelae and impaired quality of life [3–6]. Clinical strokes are
related to an up-to-nine-fold increase in postprocedural mortality [4,18,19], non-return to working life in
50% of the cases [20,21], and an increase in index hospitalization cost of approximately 25,000 USD [22].
Almost 50% of all early post-TAVR strokes are directly procedure-related and occur within the
first 24 h [3,19,23]. This post-TAVR stroke incidence peak is consistent with what has been observed
in carotid stenting procedures, suggesting that stroke occurrence is related to hostile aortic arch and
anatomical features of supra-aortic vessels [24].
CEPDs were developed with the purpose of offering a safer procedure, mitigating cerebrovascular
event risk, and improving TAVR-related outcomes [25–29]. Despite the worldwide spread of CEPD use,
evidence about anatomical features associated with its unsuccessful implantation remains scarce [29].
As bovine aortic arch is the most common aortic arch branching variant in humans, the present study
aimed to report the feasibility and safety of performing a Sentinel device insertion in this anatomy,
as well as the prevalence of bovine aortic arch anatomy in patients who underwent a protected TAVR.
Previous studies have indicated that bovine left common carotid artery configuration occurs
in 8–25% of patients [11], a prevalence similar to that observed in our cohort (12%; n = 20/165).
The presence of this type of anatomical configuration is associated with an increased endovascular
device navigation complexity [30,31]. Comparing patients with or without aortic arch anomalies
who underwent a carotid artery stent, Faggioli et al. observed that bovine arch was associated with
increased neurologic events (20% vs. 5.3%; p= 0.039) and technical failure (89.6% vs. 76.4%; p = 0.1) due
to the greater difficulty in navigating devices through tortuous vessels [30]. In addition, the presence
of increased aortic arch angulation also reflects a hostile take-off angle of the supra-aortic branches [12].
In this scenario, Rozado et al. advocated that an extreme device tip flexure could help to advance a
wire into the left carotid artery, allowing proper Sentinel advancement and positioning [32].
In our study, despite bovine aortic arch anatomy being associated with reduced two-filter insertion
(89.7% vs. 65%; p = 0.002), this feature did not reflect an increase in procedural complication rate or
postprocedural neurological events. Total procedure time (55 min vs. 55 min; p = 0.654) and volume of
contrast used (87 mL vs. 89 mL; p = 0.727) were also similar in bovine and non-bovine aortic arches.
Higher tortuosity degree and challenging device navigation were probably factors related to a lower rate
of two-filter insertion in bovine group. However, since in bovine aortic arches, both common carotid
arteries have the same origin and are in a close position, one filter properly positioned beyond their
origins is probably enough to provide adequate cerebral protection. Furthermore, even if bi-carotid
protection is not feasible, a single-filter insertion is possibly better than no cerebral protection at all.
Indeed, further computational fluid dynamics studies may shed some light on stroke risk related to
debris distribution along the arch and supra-aortic branches according to the aortic arch anatomy.
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In our study, the Sentinel was not used in 28.5% (n = 66) of patients, a rate similar to that recently
reported by Voss et al. (38.5%; n = 122). In this study, the authors reported that Sentinel ineligibility
reasons, based on MSCT criteria, were as follows: inappropriate diameter within the target landing
zone (n = 116); significant subclavian artery stenosis (n = 4) or an aberrant subclavian artery (n = 3);
and clinical characteristics including hypersensitivity to nickel titanium (n = 1), radial artery occlusion
(n = 1), or previous left common carotid artery interventions (n = 5) [33].
Another important anatomic consideration concerning Sentinel insertion eligibility is the presence
of vascular tortuosity. Tortuosity hampers access to the filter-landing zone [34–36], increasing device
manipulation, contrast use, vessel injury risk, and CEPD insertion failure [35]. Device instructions
stipulate that Sentinel should be avoided in patients with “excessive” vessel tortuosity; however,
there is no specific definition of what excessive tortuosity means. In our study, the overall prevalence
of aortic arch branches tortuosity was 16.4% (n = 27/165), with no significant difference in tortuosity
distribution between bovine and non-bovine Sentinel groups (17.2% in non-bovine vs. 2% in bovine;
p = 0.412).
Considering the benefits of cerebral protection during TAVR, even though no randomized trial
had found significant stroke or mortality reduction, a propensity-matched cohort study by Seeger et al.
identified lower mortality or all-stroke rate 7 days post-TAVR when a CEPD was used (2.1% vs. 6.8%;
p = 0.01). All-stroke rate was also inferior in protected TAVR (1.4% vs. 4.6%, p = 0.03; OR 0.29, 95% CI
0.10-0.93; NNT 31). In multivariable analysis, STS score (p = 0.02) and TAVR without cerebral protection
device (p = 0.02) were independent predictors for the primary endpoint (mortality or stroke) [37].
Two years after this initial study, the same authors evaluated the incidence of procedural stroke within
72 h post-TAVR in a propensity-matched population comprising patients from the SENTINEL US IDE
trial [24], the CLEAN-TAVI trial [34], and SENTINEL-Ulm registry (University Hospital of Ulm, Ulm,
Germany) (n = 1306). The main result showed that the procedural all-stroke rate was significantly
lower in the CEPD group compared to the unprotected group (1.88% vs. 5.44%; OR 0.35, 95% CI
0.17-0.72). In addition, the combined outcome of all-cause mortality and all-stroke was significantly
lower (2.06% vs. 6.00%; OR 0.34, 95% CI 0.17-0.68) in the protected group [38]. These findings were
supported by two recently released propensity scoring match analyses showing benefit in terms of
stroke and mortality rate reduction when Sentinel was used [9,10].
Regarding Sentinel’s cost-effectiveness, estimations show that the cost of preventing a single
stroke or death is around 60,000 USD [39]. As the Sentinel device costs approximately 2800 USD,
according to Giustino et al., a total amount of 61,600 USD should be spent to prevent one stroke or
death. This value seems to be justifiable given the negative physical, emotional, and economic impact
of stroke [40].
6. Limitations
The present analysis reflects a single-center, non-randomized, but prospectively acquired
experience. Therefore, all the inherent limitations of such design need to be taken into account.
In addition, our results are based on a single specific cerebral embolic protection device and cannot be
generalized to other available devices. Despite our small sample size, this report represents the first
cohort of patients with bovine aortic arch anatomy successfully treated with TAVR procedure under
cerebral protection.
7. Conclusions
This study demonstrated Sentinel insertion feasibility and safety in bovine aortic arch anatomy.
No procedural and access complications related to Sentinel deployment were reported. Being aware
of the bovine arch prevalence and having the techniques to navigate through it allows operators to
successfully use Sentinel in this anatomy.
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Table S1: Baseline clinical and aortic valve characteristics in patients who received or not a Sentinel device during
a transfemoral TAVR procedure; Movie S1: Sentinel cerebral protection device implanted in a bovine aortic
arch anatomy.
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